Where
Hyatt Regency McCormick Place2233 S. Martin Luther King Drive
Chicago, IL 60616
Driving Directions
Avellino Labs is the global leader in gene therapy and molecular diagnostics pioneering personalized medicine for eye care. Avellino’s Universal Test is the world’s first DNA test adopted to confirm LASIK candidates are free of genetic indicators associated with poor outcomes. Avellino Labs is also pioneering CRISPR gene editing to manage and potentially cure corneal dystrophies and other inherited eye diseases. Avellino Labs is headquartered in Silicon Valley, California with operations in Korea, Japan, China and the UK.
Avellino Labs was named a 2015 Technology Pioneer by the World Economic Forum based on its potential to impact global health.
Advancing Corneal Gene Therapy and Diagnostics by Avellino Labs
This Symposium took place during AAO 2016 in Chicago
Friday, October 14, 2016 "Advancing Corneal Gene Therapy and Diagnostics"
Keratorefractive Genetic Testing – Indications and Cases
Anthony Aldave, MD, Moderator
Speakers:
Cases by Anthony Aldave, MD, Los Angeles, CA
Cases by Eli Moses, MD, Corneal Associates of NJ
Cases by Julie Schallhorn, MD, UCSF
Gene Therapy Overview and Keratoconus Research Update
John Marshall, PhD, FMedSci
Institute of Ophthalmology, Moorefield’s Eye Hospital, London
CRISPR Gene Editing of Keratin and TGFBI Corneal Conditions in an Animal Model
Tara Moore, PhD NTF FHEA FFFLM Hon (RCP) FRSB FRSA FRSM
Ulster University, N. Ireland
Disclaimer: This event was not affiliated with the official program of AAO 2016.
Interviews during Avellino Labs Symposium
Schallhorn: Full Interview
Marshall: Full Interview
Moses: Full Interview
Cusumano: Full Interview
-
Friday, October 14, 5:00-7:00pm at the Hyatt Regency McCormick Place
Avellino Labs | 1505 Adams Drive, Suite B2 | Menlo Park, CA 94025 | +1 650 396 3741